CAJ | 학술논문

目的：探讨重组人血管内皮抑制素（恩度）联合化疗方案治疗老年结直肠癌患者的临床疗效及安全性。方法选取我院2011年1月～2013年8月收治的结直肠癌老年患者共101例，随机分为治疗组50例和对照组51例，治疗组与对照组均采用FOLFOX4（奥沙利铂+亚叶酸钙+5-氟尿嘧啶）或XELOX（奥沙利铂+卡培他滨）化疗方案，治疗组予以恩度联合化疗，比较两组间的差异。结果与对照组相比，治疗组生活质量明显改善、疾病控制率提高（P<0．05），两组不良反应率、无疾病生存期无明显统计学差异（P>0．05）。结论在老年结直肠癌患者中，恩度联合化疗可以提高疾病控制率，改善生活质量，临床耐受性良好，有较好的疗效和安全性，值得临床推广应用。
목적：탐토중조인혈관내피억제소（은도）연합화료방안치료노년결직장암환자적림상료효급안전성。방법선취아원2011년1월～2013년8월수치적결직장암노년환자공101례，수궤분위치료조50례화대조조51례，치료조여대조조균채용FOLFOX4（오사리박+아협산개+5-불뇨밀정）혹XELOX（오사리박+잡배타빈）화료방안，치료조여이은도연합화료，비교량조간적차이。결과여대조조상비，치료조생활질량명현개선、질병공제솔제고（P<0．05），량조불량반응솔、무질병생존기무명현통계학차이（P>0．05）。결론재노년결직장암환자중，은도연합화료가이제고질병공제솔，개선생활질량，림상내수성량호，유교호적료효화안전성，치득림상추엄응용。
Objective To investigate the efficacy and safety of Recombinant human endostatin combined with chemotherapy in elderly patients with colon cancer. Methods From January 2011 to August 2013, 101 elderly patients with colon cancer were divided into two groups. Chemother-apy combined with Recombinant human endostatin was administered to the treatment group(n=50), and the control group received chemotherapy only(n=51). Adverse reactions, quality of life, efficacy and time to progression were compared. Results (1) The rate of KPS score was significant im-proved in treatment group (P<0.05). (2) There was no statistical difference in adverse effect be-tween the two groups. (3) Clinical efficiency in treatment group was no better than that in control group(P<0.05). (4) There was no statistical difference in TTP between the two groups. Conclusions Recombinant human endostatin combined chemo-regimen can improve the efficacy of chemotherapy and improve quality of life, but not increase the side effects caused by chemotherapy. But whether it can improve long-term survival in colon cancer must further study.